HighBeam Research - Newspaper archives and journal articles
Options
Cancel changes
Follow us:
  • Subscription benefits
  • Log in
  • Sign up for a free, 7-day trial
  • Publications
  • Research topics
  • Topics home
  • People
    • Artists and Entertainers
    • Company executives
    • Historical figures
    • Politicians and Government officials
    • World Leaders
  • Issues and Events
    • Health and Medicine
    • Historical Events
    • Religion and Theology
    • Science and Technology
  • Places
  • Organizations
  • A-Z
    • A-G
    • H-O
    • P-T
    • U-Z
    • 0-9
  • Publications home
  • Journals
    • Academic journals
    • Business journals
    • Education journals
    • Math and Engineering journals
    • Medical journals
    • Science and Technology journals
    • Trade journals
  • Magazines
    • Business magazines
    • Computer magazines
    • Education magazines
    • Industry magazines
    • Lifestyle magazines
    • Medical magazines
  • Newspapers
    • International newspapers and newswires
    • Reports, newsletters, and transcripts
    • U.K. newspapers
    • U.S. newspapers and newswires
  • Reference works and books
    • Almanacs
    • Dictionaries and thesauruses
    • Encyclopedias
    • Non-fiction books
Home » Publications » Medical magazines » Skin & Allergy News » April 2008 »
  • Save
    This article has been saved!
    You may organize and add notes about this article below.
    This article has been saved!
    View all saved articles
  • Export

    To export this article to Microsoft Word, please log in or subscribe.

    Have an account? Please log in

    Not a subscriber? Sign up today

  • Print
  • Cite

    MLA

    Bell, John R.. "Study: oral vapitadine cuts itch without sedation.(News)." Skin & Allergy News. International Medical News Group. 2008. HighBeam Research. 19 Jun. 2013 <http://www.highbeam.com>.

    Chicago

    Bell, John R.. "Study: oral vapitadine cuts itch without sedation.(News)." Skin & Allergy News. 2008. HighBeam Research. (June 19, 2013). http://www.highbeam.com/doc/1G1-178080473.html

    APA

    Bell, John R.. "Study: oral vapitadine cuts itch without sedation.(News)." Skin & Allergy News. International Medical News Group. 2008. Retrieved June 19, 2013 from HighBeam Research: http://www.highbeam.com/doc/1G1-178080473.html

    Please use HighBeam citations as a starting point only. Not all required citation information is available for every article, and citation requirements change over time.

Study: oral vapitadine cuts itch without sedation.(News)

Skin & Allergy News
Skin & Allergy News

See all results for this publication

Browse back issues of this publication by date

April 1, 2008 | Bell, John R. | Copyright
COPYRIGHT 2009 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights or concerns about this content should be directed to Customer Service.
  • Permalink

    Create a link to this page

    Copy and paste this link tag into your Web page or blog:

    <a href="http://www.highbeam.com/doc/1G1-178080473.html" title="Study: oral vapitadine cuts itch without sedation.(News) | HighBeam Research">Study: oral vapitadine cuts itch without sedation.(News)</a>

SAN ANTONIO -- An oral formulation of the investigational drug vapitadine was found to be more effective than placebo in providing itch relief to patients with atopic dermatitis in a recent phase II study.

The drug, an [H.sub.1] antihistamine, also did not produce any sedative effects--a common criticism of other such itch-relief medications--according to the results of a randomized controlled trial presented at the annual meeting of the American Academy of Dermatology.

Braham Shroot, Ph.D., chief scientific officer of Barrier Therapeutics Inc., reported the results in a poster session on behalf of Dr. J.M. Naeyaert of the department of dermatology at the …


To read the full text of this article and others like it, try us out for 7 days, FREE!



Related articles on HighBeam Research

Chain Drug Review
Barrier's Vusion receives FDA O.K.(Barrier Therapeutics Inc.)

Chain Drug Review; May 1, 2006

700+ words
PRINCETON, N.J. -- Barrier Therapeutics Inc. has gained Food and Drug Administration approval for Vusion, billed as the first and only product specifically developed for the treatment of diaper dermatitis complicated by candidiasis (DDCC). The product continues Barrier's drive to develop a…
Drug Utilization Review
Barrier Therapeutics has begun enrolling patients in its final Phase III clinical trial for its lead product. (In the Pipeline).(Brief Article)

Drug Utilization Review; May 1, 2003

207 words
* Barrier Therapeutics has begun enrolling patients in its final Phase III clinical trial for its lead product, Zimycan, a topical ointment containing 0.25% of the antifungal miconazole, in a zinc oxide and petrolatum base. If approved, Zimycan would be the first and only product approved for use…
CCNMatthews Newswire
Barrier Therapeutics Receives Regulatory Approval to Market Xolegel in Canada

CCNMatthews Newswire; March 8, 2007

700+ words
PRINCETON, NJCCNMatthews - March 08, 2007) - Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company that develops and markets dermatology products, today announced that Health Canada's Therapeutic Products Directorate granted marketing approval to Xolegel(TM) (ketoconazole, topical…
CCNMatthews Newswire
Barrier Therapeutics Launches Denavir in Canada The Only Topical Antiviral Rx Product Approved in Canada for the Treatment of Cold Sores

CCNMatthews Newswire; August 23, 2006

643 words
PRINCETON, NJCCNMatthews - August 23, 2006) - Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced the commercial launch of Denavir(R) (penciclovir cream) 1% in Canada. Denavir is a topical antiviral…
Biotech Week
Stiefel Laboratories Completes Acquisition of Barrier Therapeutics.

Biotech Week; August 20, 2008

650 words
Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, announced that it has completed its previously announced acquisition of Princeton, New Jersey-based Barrier Therapeutics, Inc. Upon the closing of the acquisition, all remaining…
See all related articles »

Publication Finder

Browse back issues from our extensive library of more than 6,500 trusted publications.

Popular publicationson HighBeam Research

Harper's Magazine
Cultural magazines
NPR All Things Considered
News transcripts
Daily Mail (London)
U.K. newspapers
Chicago Sun-Times
Illinois newspapers
Newsweek
National newspapers

Help us improve our websites

Become a member of our Customer Advisory Panel. Your opinion matters!

Join the panel
Visit Cengage Brain
  • Company
  • About us
  • Subscription benefits
  • Group subscriptions
  • Partnership opportunities
  • Careers
  • Privacy policy
  • Terms and conditions
  • Contact us
  • Help topics
  • FAQ
  • Search tips
  • Using the Research Center
  • Billing questions
  • Rights inquiries
  • Customer Service
  • From our blog
  • All posts
  • Trending news
  • Research
  • How-to guides
  • News and updates
  • Testimonials
  • Cengage Learning Network
  • Questia
  • CengageBrain.com
  • HighBeam Business
  • Encyclopedia.com
  • ed2go
  •  
HighBeam Research
Follow us:

HighBeam Research is operated by Cengage Learning. © Copyright 2013. All rights reserved.

The HighBeam advertising network includes: womensforum.com GlamFamily